Keywords: telik, initiates, phase, iii, registration, trial, telcyta

Telik initiates Phase III registration trial of Telcyta

Article | 05 April 2004

Print This

US firm Telik has announced the initiation of a randomized Phase III registration study of Telcyta (TLK286), administered as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in